Mayo Clinic Alix School of Medicine

Research institutionUnited Statesmayoclinic.org

Mayo Clinic Alix School of Medicine serves as the medical education division of Mayo Clinic, a prominent nonprofit academic medical center dedicated to patient care, research, and education. The school offers a rigorous Doctor of Medicine program that integrates foundational medical sciences with hands-on clinical training from the early stages of the curriculum.

Read more

The institution is primarily based in Rochester, Minnesota, but extends its educational programs to campuses in Jacksonville, Florida, and Phoenix, Arizona. This multi-site structure enables students to experience a wide range of medical environments and patient populations. The school emphasizes research opportunities, allowing students to participate in cutting-edge studies in areas such as oncology, cardiology, and regenerative medicine.

As part of the larger Mayo Clinic organization, which operates as an independent nonprofit without a parent company or external ownership, the school leverages the clinic's vast clinical resources and research facilities. Mayo Clinic is recognized globally for its excellence in healthcare delivery and medical innovation.

In the medical education industry, Mayo Clinic Alix School of Medicine holds a strong position, consistently ranking among the top medical schools in the United States for both research output and primary care training. It contributes significantly to the training of physicians who go on to practice in various specialties across the country and internationally.

Also known as Mayo Medical School.

Projects Mayo Clinic Alix School of Medicine is involved in

None yet. When a new project in the record names Mayo Clinic Alix School of Medicine as owner, partner or investor, it shows here.

Active projects close to Mayo Clinic Alix School of Medicine

Mayo Clinic Alix School of Medicine in chemical industry news

20 October 2026
Novo’s CagriSema linked to ~25% weight loss in women in REDEFINE 1 post hoc analyses

Post hoc REDEFINE 1 analyses found once‑weekly cagrilintide/semaglutide produced large weight and waist‑circumference reductions across menopausal stages; main adverse events were gastrointestinal. FDA decision expected Q4 2026.